About Hives

 

Urticaria is a heterogeneous disorder characterized by the sudden appearance of wheals (raised, erythematous, edematous plaques), angioedema (deeper dermal and subcutaneous swelling), or both. Individual wheals typically resolve within 24 hours without residual skin change, distinguishing urticaria from other inflammatory dermatoses such as urticarial vasculitis, where lesions persist longer and may leave pigmentation or bruising.

Clinically, urticaria is classified by duration and trigger profile. Acute urticaria refers to episodes lasting less than six weeks and is often associated with identifiable triggers such as infections, foods, or medications. Chronic urticaria, defined as recurrent wheals or angioedema persisting beyond six weeks, is further divided into chronic spontaneous urticaria (CSU), occurring without an identifiable external trigger, and chronic inducible urticaria (CIndU), in which lesions are reliably reproduced by a specific physical stimulus. Recognized inducible subtypes include symptomatic dermographism, cold urticaria, heat urticaria, delayed pressure urticaria, solar urticaria, vibratory angioedema, cholinergic urticaria, aquagenic urticaria, and contact urticaria. Angioedema may accompany either acute or chronic disease and, when involving the airway, may constitute a medical emergency.

​

Causes

 

The pathogenesis of urticaria centers on activation of cutaneous mast cells and, to a lesser extent, basophils, with subsequent release of inflammatory mediators that produce the characteristic wheal-and-flare reaction:

The first is mast cell degranulation, the central effector event in all forms of urticaria. Activated mast cells release histamine, platelet-activating factor, prostaglandin D2, leukotrienes, cytokines, and chemokines, producing vasodilation, increased vascular permeability, sensory nerve stimulation, and recruitment of additional inflammatory cells. The second is autoimmunity, particularly relevant in chronic spontaneous urticaria, where a substantial proportion of patients demonstrate either type I autoallergy (IgE autoantibodies directed against self-antigens such as thyroperoxidase) or type IIb autoimmunity (IgG autoantibodies against the high-affinity IgE receptor FcεRI or against IgE itself), both resulting in chronic mast cell activation. The third is immunologic and non-immunologic triggers, in which mast cells are activated through IgE-mediated allergic mechanisms (foods, medications, insect venoms), direct pharmacologic mechanisms (opiates, radiocontrast media, NSAIDs), complement activation, neuropeptide release, or physical stimuli.

Secondary contributing factors and recognized triggers include viral, bacterial, and parasitic infections (a leading cause of acute urticaria, especially in children), medications (notably NSAIDs, ACE inhibitors, antibiotics, and opioids), foods and food additives, insect stings, contact allergens, psychological stress, autoimmune thyroid disease, and physical stimuli including pressure, friction, heat, cold, sunlight, and vibration. In a meaningful proportion of chronic cases, no specific trigger is identified despite thorough evaluation.

​

Treatment

 

Effective urticaria management is stepwise and individualized to disease activity, duration, trigger profile, and impact on quality of life. International guidelines, including those issued by EAACI, GA²LEN, EDF, and WAO, provide a structured therapeutic ladder that escalates according to clinical response.

First-line therapy consists of second-generation H1 antihistamines at standard licensed doses. Agents such as cetirizine, levocetirizine, loratadine, desloratadine, fexofenadine, bilastine, and rupatadine offer favorable efficacy and safety profiles, with minimal sedation and limited anticholinergic effects compared with first-generation alternatives. Continuous, rather than as-needed, dosing is preferred for chronic disease.

Second-line therapy involves up-dosing of second-generation H1 antihistamines to up to four times the standard licensed dose in patients with inadequate response, an approach supported by international consensus despite remaining off-label in many jurisdictions. The addition of an H2 antihistamine or a leukotriene receptor antagonist (montelukast) may be considered, although evidence for these adjuncts is more limited.

Third-line therapy introduces targeted biologic and immunomodulatory agents. Omalizumab, a recombinant humanized monoclonal anti-IgE antibody, is the most extensively studied biologic for chronic spontaneous urticaria and is approved for antihistamine-refractory disease, with demonstrated efficacy across both autoallergic and autoimmune endotypes. Newer agents under active investigation and increasing clinical use include ligelizumab (a higher-affinity anti-IgE antibody), dupilumab (anti–IL-4Rα), remibrutinib and other Bruton's tyrosine kinase (BTK) inhibitors, and barzolvolimab, an anti-KIT monoclonal antibody targeting mast cell survival and activation.

Fourth-line therapy comprises traditional immunosuppressants such as ciclosporin, reserved for severe, refractory chronic urticaria under specialist supervision and with appropriate monitoring. Short courses of systemic corticosteroids may be used for acute exacerbations but are not appropriate for long-term management.

Acute and emergency management of severe urticaria with angioedema, particularly involving the airway, oropharynx, or features of anaphylaxis, requires intramuscular epinephrine, oxygen, intravenous fluids, and immediate medical attention. Patients with a history of severe reactions should carry an epinephrine auto-injector and receive structured anaphylaxis action planning.

Adjunctive interventions include identification and avoidance of confirmed triggers, treatment of underlying infections or contributing conditions, management of psychological stress, and patient education on disease course, treatment adherence, and recognition of warning features.

​

Solution

 

A durable solution to urticaria is rarely a single intervention but rather a sustained, individualized regimen anchored in three principles: symptom control, trigger management, and quality-of-life support.

Symptom control begins with appropriate, continuous use of second-generation H1 antihistamines, escalated in dose and supplemented with targeted biologic therapy when standard regimens prove insufficient. Treatment intensity should be matched to disease activity using validated assessment tools such as the Urticaria Activity Score (UAS7), the Urticaria Control Test (UCT), and the Angioedema Activity Score (AAS), allowing objective tracking of response over time. Trigger management requires careful evaluation for identifiable provocateurs — including medications, infections, physical stimuli, and, less commonly, foods — supported by structured history-taking, focused investigations, and avoidance strategies tailored to the individual. Quality-of-life support acknowledges the substantial psychosocial impact of chronic urticaria, with attention to sleep, mood, work and school functioning, and the provision of appropriate psychological support where indicated.

Equally important are lifestyle considerations: avoidance of known aggravating factors such as NSAIDs in sensitive individuals, attention to skin temperature regulation in physical urticarias, stress management through behavioral and mindfulness-based interventions, and consistent communication with a healthcare provider to allow timely escalation or de-escalation of therapy. Patients should be counseled that chronic urticaria is typically a self-limiting condition over time, with the majority of cases resolving within one to five years, and that modern therapeutic options can achieve complete or near-complete symptom control in most patients while the condition runs its natural course.

With a structured, evidence-based approach and ongoing collaboration between patient and clinician, urticaria is a highly manageable condition, and meaningful, sustained improvement in skin comfort, daily functioning, and overall quality of life is an achievable outcome for the vast majority of patients.

​

Products